Report Information More information from: https ://www.wis eguyreports .com/reports /495863
Osteoporosis - Pipeline Review, H1 2016 Report / Search Code: WGR495863
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Os teoporos is - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Os teoporos is - Pipeline Review, H1 2016’, provides an overview of the Os teoporos is pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Os teoporos is , complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Os teoporos is and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Os teoporos is - The report reviews pipeline therapeutics for Os teoporos is by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Os teoporos is therapeutics and enlis ts all their major and minor projects - The report as s es s es Os teoporos is therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Os teoporos is Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Os teoporos is - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Os teoporos is
pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 7 Lis t of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Os teoporos is Overview 11 Therapeutics Development 12 Pipeline Products for Os teoporos is - Overview 12 Pipeline Products for Os teoporos is - Comparative Analys is 13 Os teoporos is - Therapeutics under Development by Companies 14 Os teoporos is - Therapeutics under Inves tigation by Univers ities /Ins titutes 20 Os teoporos is - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Os teoporos is - Products under Development by Companies 25 Os teoporos is - Products under Inves tigation by Univers ities /Ins titutes 31 Os teoporos is - Companies Involved in Therapeutics Development 32 Alethia Biotherapeutics Inc. 32 Alize Pharma SAS 33 Alkem Laboratories Ltd. 34 AlphaMab Co., Ltd 35 Amgen Inc. 36 Amura Holdings Limited 37 Arcarios BV 38 Biologics MD, Inc. 39 Bone Medical Limited 40 Bone Therapeutics SA 41 Caladrius Bios ciences , Inc. 42 Chugai Pharmaceutical Co., Ltd. 43 Clonz Biotech Private Limited 44 Corium International, Inc. 45 Critical Pharmaceuticals Limited 46 Daiichi Sankyo Company, Limited 47 ElexoPharm GmbH 48 Eli Lilly and Company 49 EndoCeutics , Inc. 50 Enteris BioPharma, Inc. 51 Enzo Biochem, Inc. 52 Gador S.A. 53 Galapagos NV 54 Glide Pharmaceutical Technologies Limited 55 Hanmi Pharmaceuticals , Co. Ltd. 56 Haoma Medica Ltd. 57 Immunovo BV 58 Kaken Pharmaceutical Co., Ltd. 59 Korea Kolmar Co. Ltd. 60 Ligand Pharmaceuticals , Inc. 61 Lotus Pharmaceutical Co., Ltd. 62 Merck & Co., Inc. 63 Mereo Biopharma Group Limited 64 Mithra Pharmaceuticals S.A. 65 Novartis AG 66 Omeros Corporation 67 Oncobiologics , Inc. 68 Os cotec Inc. 69 Os teologix Holdings Plc. 70 Paras Biopharmaceuticals Finland Oy 71 PhytoHealth Corporation 72 R-Pharm 73 Radius Health, Inc. 74 Shanghai Fudan-Z hangjiang Bio-Pharmaceutical Co., Ltd. 75 Shin Poong Pharm.Co., Ltd. 76 Sinil Pharmaceutical Co., Ltd 77 STELIS Biopharma Pvt. Ltd. 78 Sumitomo Dainippon Pharma Co., Ltd. 79 TAmiRNA GmbH 80 TechnoPhage SA 81
Terpenoid Therapeutics , Inc. 82 TSH Biopharm Corporation Limited 83 Uni-Bio Science Group Ltd. 84 Wroclaws kie Centrum Badan EIT+ Sp. z o.o. 85 Yooyoung Pharmaceutical Co., Ltd. 86 Z os ano Pharma Corporation 87 Z ydus Cadila Healthcare Limited 88 Os teoporos is - Therapeutics As s es s ment 89 As s es s ment by Monotherapy Products 89 As s es s ment by Combination Products 90 As s es s ment by Target 91 As s es s ment by Mechanis m of Action 94 As s es s ment by Route of Adminis tration 97 As s es s ment by Molecule Type 99 Drug Profiles 101 (acolbifene hydrochloride + pras terone) - Drug Profile 101 2-AMD - Drug Profile 102 2-GES - Drug Profile 103 3D-QM - Drug Profile 104 3D-QMS - Drug Profile 105 AB-25E9 - Drug Profile 106 abaloparatide - Drug Profile 107 alendronate s odium - Drug Profile 111 AM-3701 - Drug Profile 112 ARC-205 - Drug Profile 113 blos ozumab - Drug Profile 114 BMD-1111 - Drug Profile 115 BN-005 - Drug Profile 117 BN-008 - Drug Profile 118 BPS-804 - Drug Profile 119 calcitonin - Drug Profile 121 CDR-914K058 - Drug Profile 124 CDRI-99/373 - Drug Profile 125 CH-5036249 - Drug Profile 127 denos umab - Drug Profile 128 denos umab bios imilar - Drug Profile 131 denos umab bios imilar - Drug Profile 132 denos umab bios imilar - Drug Profile 133 DPF-020 - Drug Profile 134 Drug to Inhibit miR-31 for Os teoporos is - Drug Profile 135 Drug to Target miR-002 for Os teoporos is - Drug Profile 136 Drugs for Pos tmenopaus al Os teoporos is - Drug Profile 137 Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Mus culos keletal Dis orders - Drug Profile 138 DS-1501 - Drug Profile 139 eldecalcitol - Drug Profile 140 Es tetrol - Drug Profile 141 Eu-232 - Drug Profile 143 Ewha-18278 - Drug Profile 144 genipin - Drug Profile 145 HCP-1405 - Drug Profile 146 IG-8801 - Drug Profile 147 IHBD-1 - Drug Profile 148 KAL-671 - Drug Profile 149 KKM-0805 - Drug Profile 150 KKM-0902 - Drug Profile 151 KN-012 - Drug Profile 152 las ofoxifene tartrate - Drug Profile 153 MAb-7 - Drug Profile 155 Monoclonal Antibody to Inhibit Scleros tin for Os teoporos is - Drug Profile 156 MOR-106 - Drug Profile 157 NBS-101 - Drug Profile 159 NEP-28 - Drug Profile 161 OCT-1547 - Drug Profile 162 odanacatib - Drug Profile 163 ODS-656 - Drug Profile 166 Oratonin - Drug Profile 167 OXY-149 - Drug Profile 168 PHN-031 - Drug Profile 170 poncirin - Drug Profile 171 PREOB - Drug Profile 172 Proteins to Inhibit RANKL for Oncology and Os teoporos is - Drug Profile 173 R-Spondin 1 - Drug Profile 174 Recombinant Protein 1 for Rheumatoid Arthritis and Os teoporos is - Drug Profile 175 Recombinant Protein 2 for Rheumatoid Arthritis and Os teoporos is - Drug Profile 176 Recombinant Protein 3 for Rheumatoid Arthritis and Os teoporos is - Drug Profile 177 Recombinant Protein for Os teoporos is - Drug Profile 178 Recombinant Protein to Agonize PTH Receptor for Os teoporos is and Os teoarthritis -
Drug Profile 179 Recombinant Protein to Inhibit Activin A for Os teoporos is and Cancer Cachexia Drug Profile 180 Recombinant Protein to Inhibit Serine Proteas e for Bone Dis orders and Os teoporos is - Drug Profile 181 romos ozumab - Drug Profile 182 RPH-203 - Drug Profile 184 S-0071500 - Drug Profile 185 S-101479 - Drug Profile 186 S-49288 - Drug Profile 187 SI-000513 - Drug Profile 188 Small Molecule to Agonize LRP for Os teoporos is - Drug Profile 189 Small Molecule to Agonize PTH-1R for Os teoporos is - Drug Profile 190 Small Molecule to Inhibit 17beta-HSD2 for Os teoporos is - Drug Profile 191 Small Molecule to Target LGR4 for Oncology and Os teoporos is - Drug Profile 192 Small Molecule to Target OGR1 for Oncology, Bone Dis eas es , As thma and Os teoporos is - Drug Profile 193 Small Molecules for Immunology, Metabolic and Mus culos keletal Dis orders - Drug Profile 194 Small Molecules for Immunology, Mus culos keletal and Metabolic Dis orders - Drug Profile 195 Small Molecules for Os teopenia and Os teoporos is - Drug Profile 196 Small Molecules for Os teoporos is - Drug Profile 197 Small Molecules for Os teoporos is - Drug Profile 198 Small Molecules for Primary Juvenile Os teoporos is - Drug Profile 200 Small Molecules to Agonize Androgen Receptor for Os teoporos is - Drug Profile 201 Small Molecules to Agonize Glucocorticoid Receptor for Os teoporos is - Drug Profile 202 Small Molecules to Inhibit 17Beta-HSD2 for Os teoporos is - Drug Profile 203 Small Molecules to Inhibit GGDPS for Cancer and Bone Metas tas is - Drug Profile 204 Small Molecules to Inhibit Kinas e for Os teoarthritis and Os teoporos is - Drug Profile 205 Small Molecules to Inhibit NO Synthas e for Toxicology, Metabolic and Dermatology Drug Profile 206 Small Molecules to Inhibit Src Tyros ine Kinas e for Oncology, Cardiovas cular and Metabolic Dis orders - Drug Profile 207 Sodium Quinate - Drug Profile 208 SP-35454 - Drug Profile 209 SR-2595 - Drug Profile 210 Stem Cell Therapy for Os teoporos is and Periodontitis - Drug Profile 211 Synthetic Peptide for Os teoporos is - Drug Profile 212 Synthetic Peptide for Os teoporos is and Bone Fracture - Drug Profile 213 T-2GES - Drug Profile 214 teriparatide - Drug Profile 215 teriparatide - Drug Profile 217 teriparatide - Drug Profile 218 teriparatide - Drug Profile 219 teriparatide - Drug Profile 220 teriparatide - Drug Profile 221 teriparatide acetate - Drug Profile 222 teriparatide bios imilar - Drug Profile 223 teriparatide bios imilar - Drug Profile 224 teriparatide bios imilar - Drug Profile 225 teriparatide bios imilar - Drug Profile 226 TZ -121 - Drug Profile 227 Vaccine to Target Scleros tin for Os teoporos is - Drug Profile 228 VS-105 - Drug Profile 229 zoledronic acid - Drug Profile 230 Os teoporos is - Recent Pipeline Updates 232 Os teoporos is - Dormant Projects 256 Os teoporos is - Dis continued Products 267 Os teoporos is - Product Development Miles tones 269 Featured News & Pres s Releas es 269 Appendix 278 Methodology 278 Coverage 278 Secondary Res earch 278 Primary Res earch 278 Expert Panel Validation 278 Contact Us 278 Dis claimer 279 Lis t of Tables Number of Products under Development for Os teoporos is , H1 2016 20 Number of Products under Development for Os teoporos is - Comparative Analys is , H1 2016 21 Number of Products under Development by Companies , H1 2016 23 Number of Products under Development by Companies , H1 2016 (Contd..1) 24 Number of Products under Development by Companies , H1 2016 (Contd..2) 25
Number of Products under Development by Companies , H1 2016 (Contd..3) 26 Number of Products under Development by Companies , H1 2016 (Contd..4) 27 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 28 Comparative Analys is by Late Stage Development, H1 2016 29 Comparative Analys is by Clinical Stage Development, H1 2016 30 Comparative Analys is by Early Stage Development, H1 2016 31 Comparative Analys is by Unknown Stage Development, H1 2016 32 Products under Development by Companies , H1 2016 33 Products under Development by Companies , H1 2016 (Contd..1) 34 Products under Development by Companies , H1 2016 (Contd..2) 35 Products under Development by Companies , H1 2016 (Contd..3) 36 Products under Development by Companies , H1 2016 (Contd..4) 37 Products under Development by Companies , H1 2016 (Contd..5) 38 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 39 Os teoporos is - Pipeline by Alethia Biotherapeutics Inc., H1 2016 40 Os teoporos is - Pipeline by Alize Pharma SAS, H1 2016 41 Os teoporos is - Pipeline by Alkem Laboratories Ltd., H1 2016 42 Os teoporos is - Pipeline by AlphaMab Co., Ltd, H1 2016 43 Os teoporos is - Pipeline by Amgen Inc., H1 2016 44 Os teoporos is - Pipeline by Amura Holdings Limited, H1 2016 45 Os teoporos is - Pipeline by Arcarios BV, H1 2016 46 Os teoporos is - Pipeline by Biologics MD, Inc., H1 2016 47 Os teoporos is - Pipeline by Bone Medical Limited, H1 2016 48 Os teoporos is - Pipeline by Bone Therapeutics SA, H1 2016 49 Os teoporos is - Pipeline by Caladrius Bios ciences , Inc. , H1 2016 50 Os teoporos is - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 51 Os teoporos is - Pipeline by Clonz Biotech Private Limited, H1 2016 52 Os teoporos is - Pipeline by Corium International, Inc., H1 2016 53 Os teoporos is - Pipeline by Critical Pharmaceuticals Limited, H1 2016 54 Os teoporos is - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 55 Os teoporos is - Pipeline by ElexoPharm GmbH, H1 2016 56 Os teoporos is - Pipeline by Eli Lilly and Company, H1 2016 57 Os teoporos is - Pipeline by EndoCeutics , Inc., H1 2016 58 Os teoporos is - Pipeline by Enteris BioPharma, Inc., H1 2016 59 Os teoporos is - Pipeline by Enzo Biochem, Inc., H1 2016 60 Os teoporos is - Pipeline by Gador S.A., H1 2016 61 Os teoporos is - Pipeline by Galapagos NV, H1 2016 62 Os teoporos is - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 63 Os teoporos is - Pipeline by Hanmi Pharmaceuticals , Co. Ltd., H1 2016 64 Os teoporos is - Pipeline by Haoma Medica Ltd., H1 2016 65 Os teoporos is - Pipeline by Immunovo BV, H1 2016 66 Os teoporos is - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 67 Os teoporos is - Pipeline by Korea Kolmar Co. Ltd., H1 2016 68 Os teoporos is - Pipeline by Ligand Pharmaceuticals , Inc., H1 2016 69 Os teoporos is - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 70 Os teoporos is - Pipeline by Merck & Co., Inc., H1 2016 71 Os teoporos is - Pipeline by Mereo Biopharma Group Limited, H1 2016 72 Os teoporos is - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 73 Os teoporos is - Pipeline by Novartis AG, H1 2016 74 Os teoporos is - Pipeline by Omeros Corporation, H1 2016 75 Os teoporos is - Pipeline by Oncobiologics , Inc., H1 2016 76 Os teoporos is - Pipeline by Os cotec Inc., H1 2016 77 Os teoporos is - Pipeline by Os teologix Holdings Plc., H1 2016 78 Os teoporos is - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016 79 Os teoporos is - Pipeline by PhytoHealth Corporation, H1 2016 80 Os teoporos is - Pipeline by R-Pharm, H1 2016 81 Os teoporos is - Pipeline by Radius Health, Inc., H1 2016 82 Os teoporos is - Pipeline by Shanghai Fudan-Z hangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 83 Os teoporos is - Pipeline by Shin Poong Pharm.Co., Ltd., H1 2016 84 Os teoporos is - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 85 Os teoporos is - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016 86 Os teoporos is - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 87 Os teoporos is - Pipeline by TAmiRNA GmbH, H1 2016 88 Os teoporos is - Pipeline by TechnoPhage SA, H1 2016 89 Os teoporos is - Pipeline by Terpenoid Therapeutics , Inc., H1 2016 90 Os teoporos is - Pipeline by TSH Biopharm Corporation Limited, H1 2016 91 Os teoporos is - Pipeline by Uni-Bio Science Group Ltd., H1 2016 92 Os teoporos is - Pipeline by Wroclaws kie Centrum Badan EIT+ Sp. z o.o., H1 2016 93 Os teoporos is - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 94 Os teoporos is - Pipeline by Z os ano Pharma Corporation, H1 2016 95 Os teoporos is - Pipeline by Z ydus Cadila Healthcare Limited, H1 2016 96 As s es s ment by Monotherapy Products , H1 2016 97 As s es s ment by Combination Products , H1 2016 98 Number of Products by Stage and Target, H1 2016 100 Number of Products by Stage and Mechanis m of Action, H1 2016 103 Number of Products by Stage and Route of Adminis tration, H1 2016 106 Number of Products by Stage and Molecule Type, H1 2016 108
Os teoporos is Therapeutics - Recent Pipeline Updates , H1 2016 240 Os teoporos is - Dormant Projects , H1 2016 264 Os teoporos is - Dormant Projects (Contd..1), H1 2016 265 Os teoporos is - Dormant Projects (Contd..2), H1 2016 266 Os teoporos is - Dormant Projects (Contd..3), H1 2016 267 Os teoporos is - Dormant Projects (Contd..4), H1 2016 268 Os teoporos is - Dormant Projects (Contd..5), H1 2016 269 Os teoporos is - Dormant Projects (Contd..6), H1 2016 270 Os teoporos is - Dormant Projects (Contd..7), H1 2016 271 Os teoporos is - Dormant Projects (Contd..8), H1 2016 272 Os teoporos is - Dormant Projects (Contd..9), H1 2016 273 Os teoporos is - Dormant Projects (Contd..10), H1 2016 274 Os teoporos is - Dis continued Products , H1 2016 275 Os teoporos is - Dis continued Products (Contd..1), H1 2016 276 Lis t of Figures Number of Products under Development for Os teoporos is , H1 2016 20 Number of Products under Development for Os teoporos is - Comparative Analys is , H1 2016 21 Number of Products under Development by Companies , H1 2016 22 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 28 Comparative Analys is by Late Stage Development, H1 2016 29 Comparative Analys is by Clinical Stage Development, H1 2016 30 Comparative Analys is by Early Stage Products , H1 2016 31 As s es s ment by Monotherapy Products , H1 2016 97 Number of Products by Top 10 Targets , H1 2016 99 Number of Products by Stage and Top 10 Targets , H1 2016 99 Number of Products by Top 10 Mechanis m of Actions , H1 2016 102 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 102 Number of Products by Top 10 Routes of Adminis tration, H1 2016 105 Number of Products by Stage and Top 10 Routes of Adminis tration, H1 2016 105 Number of Products by Top 10 Molecule Types , H1 2016 107 Number of Products by Stage and Top 10 Molecule Types , H1 2016 107
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349